377 related articles for article (PubMed ID: 16671277)
21. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
22. Induction of pustular lesions during infliximab therapy for Crohn's disease.
Pérez-Pérez L; Caeiro JL; Fabeiro JM; Allegue F; Zulaica A
Acta Derm Venereol; 2008; 88(3):292-3. PubMed ID: 18480940
[No Abstract] [Full Text] [Related]
23. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
Ganesan S; Travis SP; Ahmad T; Jazrawi R
Curr Opin Investig Drugs; 2002 Sep; 3(9):1301-6. PubMed ID: 12498004
[TBL] [Abstract][Full Text] [Related]
24. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
Moss AC; Treister NS; Marsee DK; Cheifetz AS
Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307
[No Abstract] [Full Text] [Related]
25. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment.
Núñez Martínez O; Ripoll Noiseux C; Carneros Martín JA; González Lara V; Gregorio Marañón HG
Am J Gastroenterol; 2001 May; 96(5):1665-6. PubMed ID: 11374737
[No Abstract] [Full Text] [Related]
26. Maintenance infliximab infusions forever?
Lee SD; Surawicz CM
Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
[No Abstract] [Full Text] [Related]
27. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
28. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
29. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
30. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
31. Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases.
Nicholson T; Orangio GR; Brandenburg D; Wolf DC; Pennington EE
Dis Colon Rectum; 2005 Aug; 48(8):1651-5. PubMed ID: 15933793
[No Abstract] [Full Text] [Related]
32. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.
Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D
J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of infliximab in Crohn's disease.
Hanauer SB
N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
[No Abstract] [Full Text] [Related]
34. Infliximab in Crohn's disease: a look at the (not so distant) future.
Sorrentino D; Terrosu G; Avellini C
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S229-35. PubMed ID: 18598994
[TBL] [Abstract][Full Text] [Related]
35. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
Rahimi R; Nikfar S; Abdollahi M
Biomed Pharmacother; 2007 Jan; 61(1):75-80. PubMed ID: 17184965
[TBL] [Abstract][Full Text] [Related]
36. Balancing the risks and benefits of prolonged use of infliximab.
Schölmerich J
Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
[No Abstract] [Full Text] [Related]
37. Monoclonal antibody therapy for Crohn's disease.
Selby W
Intern Med J; 2001 Mar; 31(2):73-4. PubMed ID: 11480481
[No Abstract] [Full Text] [Related]
38. Sarcoidosis during infliximab therapy for Crohn's disease.
Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
[TBL] [Abstract][Full Text] [Related]
39. Managing complicated Crohn's disease in children and adolescents.
Homan M; Baldassano RN; Mamula P
Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):572-9. PubMed ID: 16327836
[TBL] [Abstract][Full Text] [Related]
40. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
